Rendimiento a 1 año (CAGR)
-0.48%
ALK-Abelló A/S Exchange (CO, DKK)
ALK-B.CO
207.00
+4.60 (+2.27%)
HealthcareBiotechnology
Loading...
Rendimiento a 3 años (CAGR)
37.06%
Rendimiento a 5 años (CAGR)
7.42%
Rendimiento a 10 años (CAGR)
15.76%
Adobe, tercer trimestre de 2026: ¿Está influyendo el sentimiento del mercado en el precio?
Leer másMercado
41.74B
Precio/Ventas
6.11
Valor de Ent
42.78B
Precio/Reservar
6.01
Rendimiento del div.
0.00%
Años de crecimiento
-
Crecimiento del div.
-
Pago FCF
18.84%
Seguimiento de P/E
30.78
PEG
-
P/E A plazo
28.65
EPS crecimiento
116.41%
Información sobre acciones
¿Qué es una bolsa de valores? Funcionamiento, participantes, ejemplos.
Leer másGráfico de acciones
Loading...
Datos sobre el precio de las acciones
| Abierto | 205.00 |
| Máximo diario | 211.00 |
| Mínimo diario | 205.00 |
| Volumen diario | 349K |
| Máximo histórico | 270.40 |
| Estimación de analistas a 1 año | 293.75 |
| Beta | 0.70 |
| EPS (TTM) | 6.11 |
| Dividendo por acción | 0.00 |
| Fecha ex-div | 17 Mar 2026 |
| Próxima fecha de beneficios | 20 Feb 2026 |
Potencial de desventaja
Loading...
Datos del potencial de desventaja
| ALK-B.CO | S&P500 | |
| Caída del precio actual desde el máximo histórico | -23.45% | -1.06% |
| La mayor caída de precio | -82.39% | -56.47% |
| Fecha de la mayor caída | 10 Aug 2011 | 9 Mar 2009 |
| Caída promedio del máximo | -34.19% | -10.67% |
| Tiempo promedio para un nuevo máximo | 35 days | 12 days |
| Tiempo máximo hasta el nuevo máximo | 3100 days | 1805 days |
Novedades
ALK-Abelló Pharmaceuticals Inc. Canada (ALK Canada) today announced that the Canadian Drug Expert Committee (CDEC) of Canada's Drug Agency (CDA-AMC) has issued a positive recommendation to reimburse n...
1 de octubre de 2026
ALK-Abelló (CPSE:ALK B) has reshuffled its top ranks, appointing Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy, effective 1 October 2026, as investors wei...
23 de septiembre de 2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the company’s Executive Vice President and CFO, Claus Steensen Sølje, is scheduled to participate in a fireside chat at the Morgan Stanley...
11 de septiembre de 2026
Alk-Abello AS (AKBLF) reports 18% revenue growth in Q2, driven by record tablet sales exceeding DKK1 billion, and raises full-year revenue outlook to 14%-16%.
20 de agosto de 2026
Wondering whether ALK-Abelló at DKK266.20 is still reasonably priced, or if the recent optimism has already been baked into the stock. The share price sits at DKK266.20 after returns of 0.4% over the ...
5 de junio de 2026
The current standard of care for food allergy focuses on strict avoidance of the offending allergen and the prompt use of an adrenaline auto-injector (AAI) in the event of an allergic reaction. While ...
27 de julio de 2026
ALK-Abelló (CPSE:ALK B) has drawn fresh attention after recent trading data showed a 1.5% daily return and a 7.2% gain over the past week, prompting investors to reassess the allergy specialist. See o...
2 de mayo de 2026
Inside Information ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the 2026 full-year financial outlook has been upgraded reflecting a strong growth momentum in tablet sales across regio...
7 de octubre de 2026
Inside Information Agreement provides long-term expanded access to Catalent's fast-dissolving (Zydis®) tablet formulation technology.Supply robustness secured with prioritised manufacturing capacity i...
30 de septiembre de 2026
Tina A. Olesen, Executive Vice President for Corporate, Portfolio and Product Strategy Tina A. Olesen has been appointed Executive Vice President for Corporate, Portfolio and Product Strategy at ALK, ...
21 de septiembre de 2026